VAERS 2359433
SANOFI PASTEUR · DTAP + IPV + HIB (PENTACEL) · Charge UJ529AAA
- Staat
- MD
- Alter
- 1,0
- Geschlecht
- F
- Eingang
- 06.07.2022
- Impfdatum
- 23.06.2022
- Beginn
- 23.06.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- OT / -
Symptomtext
received a dose of Pentacel and PedvaxHIB on the same day, which resulted in an extra dose of the HIB component for the patient with no reported adverse event; Initial information received on 27-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 1 years old female patient who had received a dose of pentacel and pedvaxhib on the same day, which resulted in an extra dose of the hib component for the patient with no reported adverse event while receiving vaccines PEDVAXHIB and DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL]. The patient's past medical history, medical treatment(s), concomitant medication, vaccination(s) and family history were not provided. On 23-Jun-2022, the patient received 0.5ml dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (strength, formulation was unknown, lot UJ529AAA and expiry date: 22-Jul-2022) via intramuscular route in unknown administration site for Immunization. On an unknown date, the patient received an unknown dose of suspect PEDVAXHIB not produced by Sanofi Pasteur (strength, formulation was unknown, lot UJ529AAAo and expiry date was unknown) via unknown route in unknown administration site for Prophylactic vaccination. On 23-Jun-2022 the patient developed a non-serious event received a dose of pentacel and pedvaxhib on the same day, which resulted in an extra dose of the hib component for the patient with no reported adverse event (extra dose administered) following the administration of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE and (latency: unknown) following the administration of PEDVAXHIB. Action taken : not applicable. Outcome: Unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -